ABSTRACT
Background Clostridioides difficile infection (CDI) is the most common hospital-acquired infection in the United States. Antibiotic-induced dysbiosis is the primary cause of susceptibility and fecal microbiota transplantation (FMT) has emerged as an effective therapy for recurrence. We previously demonstrated in the mouse model of CDI that antibiotic-induced dysbiosis reduced colonic expression of IL-25, and that FMT protected in part by restoring gut commensal bacteria-mediated IL-25 signaling. Here we conducted a prospective clinical trial to test the impact of FMT on immunity, specifically testing in humans if FMT induced IL-25 expression in the colon.
Methods Subjects received colonic biopsies and blood sampling at the time of FMT and 60-days later. Colon biopsies were assayed for IL-25 by immunoassay, for mRNA by RNAseq, and for bacterial content by 16 S rDNA sequencing. High dimensional flow cytometry was also conducted on peripheral blood mononuclear cells pre- and post-FMT.
Results All 10 subjects who received FMT had no CDI recurrences over a 2 year follow-up post FMT. FMT increased alpha diversity of the colonic microbiota and was associated with several immunologic changes. The cytokine IL-25 was increased in colonic tissue. In addition, increased expression of homeostatic genes and repression of inflammatory genes was observed in colonic mRNA transcripts. Finally, circulating Th17 cells were decreased post-FMT.
Conclusion The increase in the cytokine IL-25 accompanied by decreased inflammation is consistent with FMT acting in part to protect from recurrent CDI via restoration of commensal activation of type 2 immunity.
Competing Interest Statement
WP is a consultant for TechLab Inc. that makes diagnostic tests for C. difficile.
Clinical Trial
NCT02797288
Funding Statement
Research reported in this publication was supported by National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01 AI124214 and R01 AI152477 to WP. We also thank the UVA Genomics Core Facility in the Department of Biology for sequencing and library preparation for 16 S rDNA microbiota analyses (RRID:SCR_012197), the UVA SOM Flow Cytometry Core for aiding with flow cytometry and Luminex assay and the Bioinformatics Core for their help with 16 S rDNA taxonomic analyses (University of Virginia Strategic Investment Fund #162 TransUniversity Microbiome Initiative).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the UVA IRB-HSR under IRB# 18782.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials. Any other data are available from the corresponding author, CM, upon reasonable request.
